开云app官网登录入口网页版-官方正版

#达雷木单抗#

15篇内容 | 1174人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191184, encodeId=c5ef21911846d, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a> <a href='/topic/show?id=b8dc111936b6' target=_blank style='color:#2F92EE;'>#塞利尼索(selinexor)#</a>, objectTitle=Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究, objectType=article, longId=816015, objectId=03c381601523, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/ksumc-evidencebased-clinical-practice-guidelines-program-overview-20132014-1-638.jpg, objectUrl=/article/show_article.do?id=03c381601523, replyNumber=0, likeNumber=106, createdTime=2024-03-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=03c381601523, moduleTitle=Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=03c381601523)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1499939, encodeId=28861499939a8, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效, objectType=article, longId=221596, objectId=0af42215963b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af42215963b, replyNumber=0, likeNumber=71, createdTime=2021-12-07, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af42215963b, moduleTitle=Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0af42215963b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499938, encodeId=34d6149993868, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, objectType=article, longId=215765, objectId=00d1215e657e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00d1215e657e, replyNumber=0, likeNumber=63, createdTime=2021-08-17, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00d1215e657e, moduleTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=00d1215e657e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499937, encodeId=cd7f149993e0b, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, objectType=article, longId=213719, objectId=ff64213e19af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff64213e19af, replyNumber=0, likeNumber=73, createdTime=2021-07-06, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff64213e19af, moduleTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ff64213e19af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499936, encodeId=fa0a1499936fb, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Leukemia：泊马度胺、地塞米松和达雷木单抗治疗来那度胺治疗后复发的难治性多发性骨髓瘤, objectType=article, longId=212023, objectId=152e21202308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152e21202308, replyNumber=0, likeNumber=82, createdTime=2021-05-31, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152e21202308, moduleTitle=Leukemia：泊马度胺、地塞米松和达雷木单抗治疗来那度胺治疗后复发的难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=152e21202308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499935, encodeId=7758149993564, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, objectType=article, longId=211096, objectId=5efc211096c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5efc211096c3, replyNumber=0, likeNumber=0, createdTime=2021-05-12, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5efc211096c3, moduleTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5efc211096c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499934, encodeId=9a0614999349c, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, objectType=article, longId=206596, objectId=62c62065968a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c62065968a, replyNumber=0, likeNumber=66, createdTime=2021-02-03, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c62065968a, moduleTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=62c62065968a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499933, encodeId=c5211499933b1, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, objectType=article, longId=197722, objectId=54d019e7223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54d019e7223c, replyNumber=0, likeNumber=65, createdTime=2020-07-20, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54d019e7223c, moduleTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=54d019e7223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499932, encodeId=b2cb149993212, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：达雷木单抗+来那度胺+硼替佐米和地塞米松治疗新确诊的可移植的多发性骨髓瘤的疗效, objectType=article, longId=193457, objectId=c65219345ee6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65219345ee6, replyNumber=0, likeNumber=75, createdTime=2020-05-05, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65219345ee6, moduleTitle=Blood：达雷木单抗+来那度胺+硼替佐米和地塞米松治疗新确诊的可移植的多发性骨髓瘤的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c65219345ee6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499931, encodeId=686b149993141, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, objectType=article, longId=192943, objectId=28a119294391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a119294391, replyNumber=0, likeNumber=111, createdTime=2020-04-26, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a119294391, moduleTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=28a119294391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499930, encodeId=4720149993087, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：达雷木单抗联合CyBorD治疗新确诊的AL淀粉样变, objectType=article, longId=191570, objectId=b83c1915e0cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b83c1915e0cc, replyNumber=0, likeNumber=0, createdTime=2020-04-08, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b83c1915e0cc, moduleTitle=Blood：达雷木单抗联合CyBorD治疗新确诊的AL淀粉样变, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b83c1915e0cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499929, encodeId=9edc14999298d, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性, objectType=article, longId=187137, objectId=3fb318e137da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb318e137da, replyNumber=0, likeNumber=61, createdTime=2020-02-03, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb318e137da, moduleTitle=Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3fb318e137da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499928, encodeId=ff22149992882, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=174848, objectId=d8fa1e484829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8fa1e484829, replyNumber=0, likeNumber=72, createdTime=2019-07-06, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8fa1e484829, moduleTitle=Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d8fa1e484829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499927, encodeId=2736149992e94, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Lancet：VTd疗法联合达雷木单抗可进一步提高进行自体干细胞移植的多发性骨髓瘤患者的缓解率, objectType=article, longId=167616, objectId=539916e616c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=539916e616c4, replyNumber=0, likeNumber=88, createdTime=2019-06-05, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=539916e616c4, moduleTitle=Lancet：VTd疗法联合达雷木单抗可进一步提高进行自体干细胞移植的多发性骨髓瘤患者的缓解率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=539916e616c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499926, encodeId=54aa149992683, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望, objectType=article, longId=166648, objectId=b66c16664857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66c16664857, replyNumber=0, likeNumber=78, createdTime=2019-05-24, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66c16664857, moduleTitle=Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b66c16664857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, objectTitle=Blood：免疫调节剂（IMiDs）通过促进Ikaros/Aiolos降解来上调CD38，进而增强达雷木单抗介导的骨髓瘤细胞杀伤, objectType=article, longId=149170, objectId=544b1491e071, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=544b1491e071, replyNumber=0, likeNumber=0, createdTime=2018-09-22, rootId=0, userName=xuyu, userId=a1ce9392241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=544b1491e071, moduleTitle=Blood：免疫调节剂（IMiDs）通过促进Ikaros/Aiolos降解来上调CD38，进而增强达雷木单抗介导的骨髓瘤细胞杀伤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=544b1491e071)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

达雷木单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #硼替佐米# #地塞米松# #达雷木单抗# #塞利尼索(selinexor)#

Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究

2024-03-05发表于上海

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效

2021-12-07

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！

2021-08-17

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后

2021-07-06

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Leukemia：泊马度胺、地塞米松和达雷木单抗治疗来那度胺治疗后复发的难治性多发性骨髓瘤

2021-05-31

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性

2021-05-12

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）

2021-02-03

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤

2020-07-20

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：达雷木单抗+来那度胺+硼替佐米和地塞米松治疗新确诊的可移植的多发性骨髓瘤的疗效

2020-05-05

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比

2020-04-26

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：达雷木单抗联合CyBorD治疗新确诊的AL淀粉样变

2020-04-08

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性

2020-02-03

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤

2019-07-06

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Lancet：VTd疗法联合达雷木单抗可进一步提高进行自体干细胞移植的多发性骨髓瘤患者的缓解率

2019-06-05

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望

2019-05-24

xuyu (审核中...)

前往app查看评论内容

#达雷木单抗#

Blood：免疫调节剂（IMiDs）通过促进Ikaros/Aiolos降解来上调CD38，进而增强达雷木单抗介导的骨髓瘤细胞杀伤

2018-09-22

科室
- - 订阅+
  - 更多科室
工具
服务